Bar Harbor, ME
I am interested in understanding how genetic context mediates effects of environmental risk factors in neurodegenerative diseases like Alzheimer's disease.
I graduated from Emory University with a PhD in neuroscience in May of 2017, and shortly thereafter joined the Kaczorowski lab as a postdoctoral associate. I am employing a genetically diverse mouse model of Alzheimer's disease to investigate how genetic variability mediates the effects of a high fat diet on Alzheimer's-associated pathogenesis. In general, high fat diets increase risk and rate of decline in Alzheimer's disease, though in humans and in our mouse model, this is dependent on an individual's genetic context. I use a variety of behavioral, molecular, and computational techniques which will precisely identify which gene candidates and molecular networks are responsible for regulating this variability. Ultimately, these studies should lead to novel therapeutic targets for more personalized treatment strategies for Alzheimer's disease.
Emory University Ph.D., Neuroscience Advisor: Dr. Gary W. Miller 2011-2017
University of Maine B.A., Psychology 2007-2010
Dunn, A.R., Ozawa, M., Stout, K.A., Bradner, J.M., Dhamsania, R.K., Miller, G.W. 2017. Immunochemical analysis of the synaptic vesicle glycoprotein 2C (SV2C) in mouse, macaque and human basal ganglia. Brain Research, in press.
Dunn, A.R., Stout, K.A., Ozawa, M., Lohr, K.M., Bernstein, A.I., Li, Y., Wang, M., Sgobio, C., Sastry, N., Cai, H., Caudle, W.M., Miller, G.W. 2017. The synaptic vesicle glycoprotein 2C (SV2C) mediates dopamine release and is disrupted in Parkinson’s disease. Proceedings of the National Academy of Sciences. 114(11) E2253-62.
Stout, K.A., Dunn, A.R., Lohr, K.M., Ozawa, M., Alter, S.P., Guillot, T.S., Miller, G.W. 2016. Selective enhancement of dopamine release in the ventral pallidum of methamphetamine-sensitized mice. ACS Chemical Neuroscience, 7(10): 1364-1373.
Lohr, K.M., Stout, K.A., Dunn, A.R., Wang, M., Salahpour, A., Guillot, T.S., Miller, G.W. 2015. Increased vesicular monoamine transporter 2 (VMAT2; Slc18a2) protects against methamphetamine toxicity. ACS Chemical Neuroscience, 6(5):790-9.
Lohr, K.M., Bernstein, A.I., Stout, K.A., Dunn, A.R., Lazo, C.R., Alter, S.P., Wang, M., Li, Y., Fan, X., Hess, E.J., Yi, H., Vecchio, L.M., Goldstein, D.S., Guillot, T.S., Salahpour, A., Miller, G.W. 2014. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson’s disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences, 111(27), 9977-82.